Shattuck Labs Announces Participation in Upcoming May Conferences

Rhea-AI Summary

Shattuck Labs (NASDAQ: STTK), a biotechnology firm, announced participation in two upcoming conferences. CEO Taylor Schreiber will discuss multifunctional soluble biologics at the 32^nd Annual Cello Health Cancer Progress Conference on May 5, 2021, and ranking product attributes at the 17^th Annual PEGS Boston Conference on May 11, 2021. The company focuses on developing bi-functional fusion proteins targeting cancer and autoimmune diseases, led by the SL-172154 program in Phase 1 trials, designed to block immune checkpoints.

Positive

• CEO participation in high-profile conferences which may enhance visibility.
• Ongoing Phase 1 trials for lead compound SL-172154 could attract investor interest and validate technology.

Negative

• None.

AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, will participate in two upcoming conferences.

Presentation Details
Conference: 32^nd Annual Cello Health Cancer Progress Conference
Title: Multifunctional Soluble Biologics: Binders, Binders Everywhere
Format: Panel discussion
Date: May 5, 2021
Time: 11:45 a.m. EST

Conference: 17^th Annual PEGS Boston Conference
Title: Ranking Product Attributes to Select an Appropriate Expression Platform
Format: Panel discussion
Date: May 11, 2021
Time: 12:20 p.m. EST

The presentations and panel discussions will be available to registered conference attendees.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com 

FAQ

What will Shattuck Labs' CEO discuss at the upcoming conferences?

CEO Taylor Schreiber will discuss multifunctional soluble biologics at the Cello Health Cancer Progress Conference and ranking product attributes at the PEGS Boston Conference.

When are the upcoming conferences for Shattuck Labs?

The conferences are scheduled for May 5, 2021, and May 11, 2021.

What is the stock symbol for Shattuck Labs?

The stock symbol for Shattuck Labs is STTK.

What is Shattuck Labs' lead program in clinical trials?

Shattuck Labs' lead program is SL-172154, which is currently in Phase 1 trials.

What are the therapeutic targets of Shattuck Labs' products?

Shattuck Labs develops biologic medicines targeting cancer and autoimmune diseases.